<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00031889</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 09/01</org_study_id>
    <secondary_id>EU-20139</secondary_id>
    <nct_id>NCT00031889</nct_id>
  </id_info>
  <brief_title>Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer</brief_title>
  <official_title>A Randomized Phase II Trial of Exemestane With and Without Bicalutamide as Second Line Therapy After Failure of Androgen Suppression in Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using&#xD;
      exemestane plus bicalutamide may fight prostate cancer by reducing the production of&#xD;
      androgens. It is not yet known if exemestane is more effective with or without bicalutamide&#xD;
      in treating prostate cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to study the effectiveness of exemestane with or without&#xD;
      bicalutamide in treating patients who have stage IV prostate cancer that has been previously&#xD;
      treated with hormone therapy or surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy and tolerability of exemestane with or without bicalutamide as&#xD;
           second-line therapy after failure of androgen suppression (luteinizing hormone-releasing&#xD;
           hormone agonist or orchiectomy) in patients with stage IV prostate cancer.&#xD;
&#xD;
        -  Determine the potential antagonistic effect of the weak androgen action of exemestane&#xD;
           when combined with bicalutamide in these patients.&#xD;
&#xD;
        -  Compare the quality of life (QOL) in patients treated with these regimens.&#xD;
&#xD;
        -  Correlate prostate-specific antigen response and data of QOL, including scores for pain&#xD;
           intensity and analgesic consumption, in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      performance status (0 vs 1-2), pain (none or mild vs moderate or severe), and participating&#xD;
      center. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral exemestane once daily.&#xD;
&#xD;
        -  Arm II: Patients receive exemestane as in arm I and oral bicalutamide once daily.&#xD;
&#xD;
      Treatment in both arms continues every 4 weeks for a minimum of 2 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life and pain are assessed at baseline, on day 1 of course 2 and any subsequent&#xD;
      courses, and at disease progression or treatment failure (if applicable).&#xD;
&#xD;
      Patients are followed monthly until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-62 patients (10-31 per treatment arm) will be accrued for&#xD;
      this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">June 2002</completion_date>
  <primary_completion_date type="Actual">June 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive oral exemestane once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive exemestane as in arm I and oral bicalutamide once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Exemestane</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane+bicalutamide</intervention_name>
    <description>Exemestane as in arm I and oral bicalutamide once daily</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed stage IV adenocarcinoma of the prostate&#xD;
&#xD;
          -  Documented disease progression based on prostate-specific antigen (PSA) progression&#xD;
             during first-line androgen suppression (luteinizing hormone-releasing hormone agonist&#xD;
             or orchiectomy)&#xD;
&#xD;
               -  PSA progression is defined by the following:&#xD;
&#xD;
                    -  Interval of at least 1 week between reference value (time point value 1) and&#xD;
                       the next PSA level (time point value 2)&#xD;
&#xD;
                    -  PSA at time point value 3 is greater than PSA at time point value 2 OR&#xD;
&#xD;
                    -  PSA at time point value 3 is not greater than PSA at time point value 2, but&#xD;
                       PSA at time point value 4 is greater than PSA at time point value 2&#xD;
&#xD;
          -  PSA at least 5 ng/mL&#xD;
&#xD;
          -  Must continue primary androgen suppression if no prior surgical castration&#xD;
&#xD;
          -  No known leptomeningeal or brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,500/mm^3&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No acute concurrent severe infection&#xD;
&#xD;
          -  No other concurrent significant disease that would preclude study therapy&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated basal cell or&#xD;
             squamous cell skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior antibody or gene therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior cytostatic agents&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior estramustine&#xD;
&#xD;
          -  No prior antiandrogens (e.g., bicalutamide)&#xD;
&#xD;
          -  No concurrent estrogen-containing medicine&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy to more than 1 field&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 4 weeks since prior investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Bonomo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ospedale Beata Vergine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital, Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Biel</name>
      <address>
        <city>Biel</city>
        <zip>CH-2500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <zip>CH-4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ratisches Kantons und Regionalspital</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique De Genolier</name>
      <address>
        <city>Genolier</city>
        <zip>Ch-1272</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana</name>
      <address>
        <city>Lugano</city>
        <zip>CH-6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Beata Vergine</name>
      <address>
        <city>Mendrisio</city>
        <zip>CH-6850</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Central des Hopitaux Valaisans</name>
      <address>
        <city>Sion</city>
        <zip>CH1951</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>March 8, 2002</study_first_submitted>
  <study_first_submitted_qc>June 30, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2003</study_first_posted>
  <last_update_submitted>May 14, 2012</last_update_submitted>
  <last_update_submitted_qc>May 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

